Although approved to treat 38 CF variants with residual functions, Ivacaftor (VX-770) however does not fully restore CFTR function of some of these CF variants with gating mutations (e.g. G551D-CFTR)33 to wild-type level. This evidence concerns the gene CFTR and cystic fibrosis.